parthenolide has been researched along with Cancer of Pancreas in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nair, HN; Pratihar, D; Ramachandran, PV; Schmidt, CM; Smith, S; Walters, M; Wu, H; Yip-Schneider, MT | 1 |
| Bryant, VC; Kishore Kumar, GD; Natarajan, A; Nyong, AM | 1 |
| Helppi, MA; Lehmkuhler, AL; Marchi, JM; Ramachandran, PV; Schmidt, CM; Yip-Schneider, MT | 1 |
| Gagare, PD; Helppi, MA; Nair, HN; Nicponski, DR; Ramachandran, PV; Schmidt, CM; Yip-Schneider, MT | 1 |
| Adachi, M; Wang, W; Zhang, R; Zhou, J; Zhu, D | 1 |
| Cai, MX; Huang, DS; Liu, JW; Ma, J; Wu, QS; Xie, HY; Xin, Y; Yang, P | 1 |
| Marshall, MS; Nakshatri, H; Schmidt, CM; Sweeney, CJ; Wiebke, EA; Yip-Schneider, MT | 1 |
| Crooks, PA; Nakshatri, H; Neelakantan, S; Noble, S; Ralstin, M; Schmidt, CM; Sweeney, CJ; Wu, H; Yiannoutsos, C; Yip-Schneider, MT | 1 |
8 other study(ies) available for parthenolide and Cancer of Pancreas
| Article | Year |
|---|---|
Tailored α-methylene-γ-butyrolactones and their effects on growth suppression in pancreatic carcinoma cells.
Topics: 4-Butyrolactone; Cell Division; Cell Line, Tumor; Humans; Pancreatic Neoplasms | 2010 |
Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs.
Topics: Antineoplastic Agents; Apoptosis; Biological Products; Cell Line; Chemistry, Pharmaceutical; Drug Design; Ether; HEK293 Cells; Humans; Models, Chemical; NF-kappa B; Pancreatic Neoplasms; Time Factors; Tumor Necrosis Factor-alpha | 2012 |
Factors influencing the cytotoxicity of α-methylene-γ-hydroxy esters against pancreatic cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esters; Humans; Molecular Structure; Pancreatic Neoplasms; Structure-Activity Relationship | 2015 |
Synthetic α-(aminomethyl)-γ-butyrolactones and their anti-pancreatic cancer activities.
Topics: 4-Butyrolactone; Amination; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Humans; Pancreatic Neoplasms; Sesquiterpenes; Stereoisomerism; Structure-Activity Relationship | 2013 |
A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Growth Inhibitors; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Oxides; Pancreatic Neoplasms; Reactive Oxygen Species; Sesquiterpenes; Xenograft Model Antitumor Assays | 2009 |
Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Cell Proliferation; Flow Cytometry; Humans; Immunoenzyme Techniques; In Vitro Techniques; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sesquiterpenes; Tumor Cells, Cultured | 2010 |
Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Models, Biological; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Protein Binding; Sesquiterpenes; Sulindac; Transcription, Genetic; Transfection | 2005 |
Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin D1; Humans; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Sesquiterpenes; Sulindac | 2007 |